Idazoxan inhibits hyperprolactinaemia in ovariectomized estrogen-treated rats
Autor: | E. Lacroix, W. Eechaute, P. Preziosi, P. Navarra |
---|---|
Rok vydání: | 1991 |
Předmět: |
endocrine system
medicine.medical_specialty endocrine system diseases medicine.drug_class Endocrinology Diabetes and Metabolism Ovariectomy Clinical Biochemistry Serotonergic Biochemistry Dioxanes Endocrinology Idazoxan Internal medicine medicine Animals Estrous cycle Estradiol Chemistry Biochemistry (medical) Hyperprolactinaemia Antagonist Rats Inbred Strains General Medicine medicine.disease Prolactin Rats Hyperprolactinemia Estrogen Ovariectomized rat Female Proestrus hormones hormone substitutes and hormone antagonists medicine.drug |
Zdroj: | Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme. 23(1) |
ISSN: | 0018-5043 |
Popis: | The alpha 2-antagonist idazoxan (IDZ) has previously been shown to inhibit hyperprolactinaemia triggered by various stimuli such as lactation, stress, serotonergic agents and morphine (Preziosi, Martire, Navarra, Pistritto and Vacca 1989; Krulich, Jurcovicova and Le 1989). In this study, we investigated the PRL-lowering activity of IDZ in ovariectomized estrogen-treated (OET) rats; since a PRL surge usually occurs in normal cycling rats on the day of proestrus, the effect of IDZ on pulsatile PRL release in intact female rats was also studied. IDZ significantly lowered plasma PRL levels in OET rats; no elevated PRL values were observed in normal cycling rats, indicating that IDZ might inhibit PRL surges in these animals. It is concluded that IDZ is an effective PRL-lowering agent in a number of physiological and pharmacological hyperprolactinaemic models. |
Databáze: | OpenAIRE |
Externí odkaz: |